• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Baxter, Harvard launch Opsonix

Baxter, Harvard launch Opsonix

October 9, 2015
CenterWatch Staff

Cambridge, Mass.-based Opsonix has launched with an $8 million Series A financing to develop a pathogen-extracting therapy designed to remove infectious pathogens and toxins from circulating blood.

The treatment potentially offers a new broad-spectrum approach to treat blood-borne infectious diseases, including sepsis. Opsonix will use the proceeds from the financing to advance the development of its extracorporeal pathogen-extracting therapy. The Series A financing was led by Baxter Ventures, alongside of investment by private investor Hansjörg Wyss.

Opsonix’s core technology is based on proprietary pathogen-capture proteins. Its lead molecule is a recombinant human protein derived from mannose binding lectin (MBL) fused to the Fc region of human immunoglobulin (FcMBL). When Opsonix’s FcMBL is attached to the membrane of a dialyzer-type device, it can remove a broad range of bacteria, fungi, parasites, viruses and toxins responsible for initiating the sepsis cascade, including antibiotic-resistant organisms. Opsonix’s pathogen-extracting therapy has been designed to work in synergy with conventional antibiotic treatments.

Opsonix’s scientific founders, Donald Ingber, M.D., Ph.D., and Michael Super, Ph.D., carried out the original protein engineering and initial design and experimental validation of the FcMBL-enabled pathogen-extracting therapy at the Wyss Institute for Biologically Inspired Engineering at Harvard University. Ingber and Super are pioneers in translating innovative design principles into healthcare products. They are also co-Principal Investigators on a project for sepsis treatment funded by the U.S. Defense Advanced Research Projects Agency (DARPA) Dialysis-Like Therapeutics Program, which led to the technology that Opsonix is commercializing.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing